News & Media
Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.
Director, External Communications,
Otsuka America Pharmaceutical, Inc
Otsuka America Pharmaceutical, Inc. announces that it will integrate Avanir Pharmaceuticals into its business as of January 1, 2023. The move brings together the knowledge, capabilities and best practices of both companies to further advance solutions to treat central nervous system disorders.
Otsuka and Lundbeck announce the U.S. Food and Drug Administration (FDA) acceptance of their New Drug Application (NDA) for aripiprazole 2-month, ready-to-use, long-acting injectable, a medication administered for the treatment of schizophrenia in adults and for maintenance monotherapy treatment of bipolar I disorder in adults.
The Satcher Health Leadership Institute at Morehouse School of Medicine (SHLI), with support from Otsuka America Pharmaceutical, Inc., a leader in mental health, released The Economic Burden of Mental Health Inequities in the United States Report. SHLI looked at a four-year period (2016-2020) and found, at minimum, nearly 117,000 lives and approximately $278 billion could have been saved. The full report is now available for download.
People living with serious mental illness (SMI) are at higher risk for a wide range of chronic physical conditions, are more likely to visit the emergency department, be admitted to the hospital and have longer hospital stays compared to those without SMI. Nonadherence to drug treatments for major depressive disorder (MDD), schizophrenia and bipolar disorder is common. Several studies illustrate the problem, estimating that up to half of patients with bipolar disorder, MDD and/or schizophrenia do not take their medication as directed.